Areas of focus
We have a strong history of addressing some of the most critical unmet clinical needs and are well placed to help societies across Europe address today’s health challenges.
We work tirelessly to protect people from the threat of infectious diseases and to help people to live a healthy and prosperous life.
Infectious diseases
We are a leader in the discovery and development of treatments for infectious diseases, demonstrated by our track record in combatting diseases such as HIV and influenza, and the key role we play in the fight against antimicrobial resistance. Our hospital focus aims to address high-impact infectious diseases that threaten society, including:
Antibiotics
We developed a new antibiotic that targets multidrug resistant Gram-negative bacteria, which is a major global public health concern.
HIV therapy
As the R&D engine of ViiV Healthcare, we developed two of the most important HIV medications in the last decade.
Influenza treatment and prevention
We discovered an anti-viral drug for the treatment and post-exposure prophylaxis of the influenza virus.
COVID-19
In line with our commitment to combating infectious diseases, we are focused on playing our part in solving the ongoing challenges posed by COVID-19.
Serious Fungal Infection
Our work in anti-fungal agents aims to address unmet clinical needs caused by drug restant aspergillus and other rarer mould infections.
Diseases and therapy areas affecting quality of life, with high social impact
We are determined to contribute to people’s ability to live a healthy and prosperous life. As part of this aim, we are passionate about finding opportunities to support the millions of people who live with a rare disease.
Living with a rare condition can profoundly impact every aspect of life, from the uncertainty in diagnosis, to the challenges of managing symptoms and accessing care, the journey can be overwhelming and isolating.
That’s why we want to play our part in addressing the unmet needs of patients with rare diseases and their families and caregivers.
A core part of our global strategy is to focus on developing innovative medicines that address unmet needs within disease areas that impact people’s quality of life.
Through the delivery of this strategy, we are evolving to become a global commercially integrated organisation that operates in a number of therapeutic areas where there are extremely limited or no other treatment options, while continuing to solidify our place as the infectious diseases powerhouse we are known for.
Our rapidly growing pipeline demonstrates our commitment to finding treatments for rare diseases.
In the area of women's health we have created a therapy to combat vulvar and vaginal atrophy. This condition occurs post-menopause and results in thinning of vaginal epithelial cells, reduced elasticity, and decreased vaginal secretion due to declining oestrogen levels.
Within our work to improve the quality of life for people who suffer from pain, we developed a medication for the treatment of opioid induced constipation (OIC) in adult patients who have previously been treated with a laxative.
We continue to focus on addressing areas of unmet need, such as hearing loss, dementia, obesity, sleep disorders and paediatric care.